Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2007

View Archived Issues

Interleukins in dermatology

Kosan receives SPA for TIME-1 trial of tanespimycin in multiple myeloma

Extinction of learned responses to fear regulated by Cdk5 signaling in hippocampus / News in Context

Late phase II trials for ART-123 begin

ThromboGenics and BioInvent state positive results from TB-402 phase I clinical trial

Fennobon launches cholesterol-lowering chewing gum with Reducol

Athersys completes name change

Update on ReNeuron's ReN-001 stem cell therapy for stroke

Tikvah and Chakra to codevelop four novel antipsychotic compounds

Update on Alba Therapeutics' AT-1001 IND for type 1 diabetes

Health Canada makes changes in Ketek indications

Sirtris and NIA sign CRADA for SIRT1 activators in aging

Two-year collaboration agreement signed by Aradigm and CyDex

PAR-1 inhibition by SCH-602539 shows antithrombotic effects in vivo

MHLW approves Taiho's antimetabolite TS1 capsules for biliary cancer

Selective tissue targeting with novel siRNA delivery technology

AtheroGenics announces new data on AGI-1067 in diabetes

Update on Salix's pipeline

Nabi reports interim results from phase IIb trial of NicVAX

Positive results for Plethora Solutions' phase II study of PSD-597 for interstitial cystitis

Studies advance clinical development of almorexant for insomnia

New antiglaucoma agents jointly imparted by NicOx and Pfizer

Recent Pfizer patents disclose novel antibacterial agents

New agents for treating neurological disorders disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...